Christopher Pargellis

Statistics

Publications

Citations

1.5K

H-Index

Active since

1985

Affiliations

Boehringer Ingelheim (United States)(Current)

Boehringer Ingelheim (Japan)

Boehringer Ingelheim (Germany)

Brown University

Boehringer Ingelheim (Brazil)

Christopher Pargellis is an author at Boehringer Ingelheim (United States) specializing in pharmacology, life sciences, and p38 mitogen-activated protein kinase signaling.

Publications per year

1985–2008

Publications

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

Christopher Pargellis, Liang Tong, Laurie Churchill et al. · Nature Structural Biology · 2002 · 834 citations · Full text

Life Sciences, Immunology, Molecular Biology +15

Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase

K.A. Cohen, John Hopkins, Richard H. Ingraham et al. · Journal of Biological Chemistry · 1991 · 116 citations · Full text

Medicine, Biochemistry, Pharmacology +15

Discovery and Characterization of a Substrate Selective p38α Inhibitor

Walter Davidson, Lee Frego, Gregory W. Peet et al. · Biochemistry · 2004 · 110 citations

Life Sciences, Biochemistry, Pharmacology +17

Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease

Daniel Lamarre, G Croteau, Elizabeth Wardrop et al. · Antimicrobial Agents and Chemotherapy · 1997 · 74 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17

Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures.

Susan Pav, Christopher Pargellis, Daniel Lamarre et al. · Proceedings of the National Academy of Sciences · 1993 · 66 citations

Life Sciences, Medicinal Chemistry, Molecular Biology +15

1–5 of 12